Multimodal drug infiltration during bone marrow aspiration. A randomized dubble blind controlled study

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-012479-93-SE

Enrollment

200

Registered

2009-06-03

Start date

2009-09-09

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Procedure pain for bone marrow aspiration, and painscore during 24 hour after aspiration

Interventions

Trade Name: Narop Product Name: Narop Product Code: NO1BB09 Pharmaceutical Form: Solution for injection Trade Name: Toradol Product Name: Toradol Pharmaceutical Form: Injection* Trade Name: Adrenali

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Twohundered adult males and females undergoing bone marrow aspiration who have signed informed consent. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Allergy for NSAID or local anesthetic, psychiatric disorders, demens, AV-block III, cardiac disorders, ulcus ventriculi and duodeni, renal disorders, coagulation disorders and patients who refuses to participate.

Design outcomes

Primary

Measure	Time frame
Secondary Objective: Pain score during first 24 hour after aspiration procedure;Primary end point(s): Painintensity (VAS) during bone marrow punkture. ;Main Objective: Pain score during bone marrow aspiration procedure	—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026